Company: CERO
Filing Date: 2025-05-27
Form Type: POS AM
Source: 0001213900-25-047469
Chunk: 147

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-27
Form: POS AM
Chunk 147
---
 all outstanding Warrants and options), adjusted to include the issuance of the number of Keystone Purchase Shares set forth in the adjacent column which we would have issued to Keystone based on the applicable assumed purchase price per share. |

| (3) | The Company will not receive any proceeds from the issuance of the Keystone Commitment Shares. |

| (4) | Represents the last reported sales price of the Common Stock on May 19, 2025, as reported by Nasdaq, less a 10% discount. |

Notwithstanding the foregoing, we may not issue, and Keystone may not sell, more than an aggregate of 2,100,000 shares registered under pursuant to this registration statement, of which 1,377,950 November 2024 Keystone Purchase Shares remain available for issuance and resale hereunder. We will need to file a new registration statement, which must be declared effective, before we may issue, and Keystone may sell, any additional shares in excess of such November 2024 Keystone Purchase Shares that remain available for issuance and sale hereunder. 78 USE OF PROCEEDS All of the shares of our Common Stock offered by Keystone will be solely for Keystone’s account. We will not receive any of the proceeds from these sales. In addition, we will not receive any proceeds from the issuance or sale of the Keystone Commitment Shares. We may receive up to $25.0 million in aggregate gross proceeds from Keystone under the Keystone Purchase Agreements in connection with sales of our shares of our Common Stock to Keystone pursuant to the Keystone Purchase Agreements after the date of this prospectus. However, the actual proceeds may be less than this amount depending on the number of share of our shares of our Common Stock sold and the price at which the shares of our Common Stock are sold. We intend to use any net proceeds from any sales of shares of our Common Stock to Keystone under the Keystone Equity Financing for working capital and other general corporate purposes. Pending other uses, we intend to invest the net proceeds to us in investment-grade, interest-bearing securities such as money market funds, certificates of deposit, or direct or guaranteed obligations of the U.S. government, or hold as cash. We cannot predict whether the net proceeds invested will yield a favorable return. We will have broad discretion in the way we use these proceeds. See “ Risk Factors-Risks Related to the Keystone Equity Financing-We may use proceeds from sales of our Common Stock made pursuant to the Keystone Purchase Agreements in ways with which you may not agree or in ways which may